Traders Purchase High Volume of Call Options on Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDGet Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 14,742 call options on the company. This represents an increase of approximately 45% compared to the typical volume of 10,166 call options.

Gilead Sciences Stock Down 0.4 %

NASDAQ GILD opened at $97.99 on Wednesday. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $99.45. The stock has a market capitalization of $122.12 billion, a PE ratio of 1,088.78, a PEG ratio of 1.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business’s 50-day moving average is $92.58 and its 200 day moving average is $86.14.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $2.29 EPS. Sell-side analysts forecast that Gilead Sciences will post 4.34 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock worth $53,611,715 over the last quarter. 0.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GILD. Bellevue Group AG lifted its holdings in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after buying an additional 7,093 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares during the period. McAdam LLC boosted its position in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares in the last quarter. IRON Financial LLC purchased a new stake in Gilead Sciences in the third quarter worth $830,000. Finally, Capital Investment Advisors LLC raised its holdings in Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after purchasing an additional 9,791 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wolfe Research began coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Robert W. Baird upped their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Read Our Latest Analysis on GILD

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.